Scisparc finalizes exclusive global out-licensing agreement for its pain therapy valued at $3 million

Scisparc will receive consideration in shares, and in addition may receive cash payments and fees if certain development milestones are met

SPRC Ratings Summary

SPRC Quant Ranking